Troglitazone (Rezulin, Resulin, Romozin, Noscal) is an antidiabetic and anti-
inflammatory drug, and a member of the drug class of the thiazolidinediones.
Learn about Rezulin (Troglitazone (removed from the US market 3/21/00)) may
treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, ...
BACKGROUND: Troglitazone was removed from the U.S. market because its use
was associated with an increased risk of liver failure. We evaluated the clinical ...
Learn about the potential side effects of troglitazone. Includes common and rare
side effects information for consumers and healthcare professionals.
EDITORIALS. Insight Into Hepatotoxicity: The Troglitazone. Experience. See
Article on Page 237. Troglitazone entered the U.S. market in 1997 as the first
FDA Endocrine and Metabolic Drugs Advisory Committee Meeting on
Troglitazone. The last time I appeared before this advisory committee to present ...
Troglitazone, a peroxisome proliferator–activated receptor gamma agonist, which
enhances insulin sensitivity, was approved for the treatment of type 2 diabetes ...
Aug 14, 2013 ... Rezulin (troglitazone). Parke-Davis/Warner Lambert agree to FDA's request to
withdraw Rezulin from the market. FDA asked ...
Troglitazone (Romglizone, BRN 4338399, CS-045, CI-991, GR 92132X), CAS
97322-87-7, high purity chemical. Synthetic. PPARgamma agonist. Anti-diabetic
View and buy high purity Troglitazone from Tocris Bioscience, the leading
worldwide supplier of high performance life science reagents.